Biotricity (BTCY) Stock Price, News & Analysis

Company Overview

Biotricity, Inc. (NASDAQ:BTCY) is a digital health company specializing in remote patient monitoring solutions across cardiovascular and chronic disease management. The firm develops and commercializes a patented wearable biosensor platform designed to capture continuous physiological data, including electrocardiogram (ECG) readings and heart rate variability. This integrated system combines lightweight, adhesive biosensors with cloud-based analytics and clinician-facing software to support early detection of cardiac arrhythmias and facilitate telehealth care delivery.

The company’s flagship offering, the Bioflux™ platform, comprises a small, single-use wearable device that transmits real-time data to a secure portal, where advanced algorithms analyze cardiac patterns and generate clinician alerts. Complementing the hardware are subscription-based services—such as Bioflux™ Rx—through which Biotricity provides end-to-end monitoring programs under a prescription model. These programs enable cardiologists, primary care physicians, and remote monitoring centers to review patient data remotely, optimize treatment plans and enhance patient engagement without the need for in-office visits.

Founded in 2015 and headquartered in Menlo Park, California, Biotricity serves healthcare providers and payors throughout the United States, with emerging international partnerships aimed at expanding telemedicine adoption. Under the leadership of Founder and Chief Executive Officer Amir Kalali, the company has secured regulatory clearances for multiple product lines and continues to invest in research and development to broaden its digital health ecosystem. Biotricity’s solutions target efficient, patient-centric care by leveraging real-world data and scalable technology to address growing demands for remote monitoring in modern healthcare.

Key Stats

• Today's Range: $0.61 to $0.75
• 50-Day Range: $0.36 to $0.71
• 52-Week Range: $0.19 to $0.83
• Volume: 14,577 shs
• Average Volume: 37,897 shs
• Market Capitalization: $16.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

BTCY Stock Analysis - Frequently Asked Questions

How have BTCY shares performed this year?

Biotricity's stock was trading at $0.2899 at the beginning of 2025. Since then, BTCY shares have increased by 138.8% and is now trading at $0.6922.

How were Biotricity's earnings last quarter?

Biotricity, Inc. (NASDAQ:BTCY) posted its quarterly earnings data on Thursday, June, 27th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.11. The business had revenue of $3.18 million for the quarter, compared to analysts' expectations of $3.20 million.

When did Biotricity IPO?

Biotricity (BTCY) raised $15 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 5,000,000 shares at $3.00 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.

How do I buy shares of Biotricity?

Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biotricity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotricity investors own include Transdigm Group (TDG), Taiwan Semiconductor Manufacturing (TSM), Wix.com (WIX), Datadog (DDOG), Quanta Services (PWR), PayPal (PYPL) and Royal Caribbean Cruises (RCL).

Company Calendar

• Last Earnings: 6/27/2024
• Today: 9/10/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BTCY
• CIK: 1630113
• Web: www.biotricity.com
• Phone: (800) 590-4155
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.09 million
• Net Margins: -80.42%
• Pretax Margin: -80.42%
• Return on Equity: N/A
• Return on Assets: -188.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.23
• Quick Ratio: 0.10

Sales & Book Value

• Annual Sales: $12.06 million
• Price / Sales: 1.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.30) per share
• Price / Book: -0.54

Miscellaneous

• Outstanding Shares: 24,912,000
• Free Float: 22,075,000
• Market Cap: $17.60 million
• Optionable: Optionable
• Beta: 1.18